1. Polychronis Pavlidis, Fergus JQ Chedgy and Jeremy A Tibble. 
Diagnostic accuracy and clinical application of faecal calprotectin in adult patients presenting with gastrointestinal symptoms in primary care. 

2. Emanuel Burri, Michael Manz, Claude Rothen, Livio Rossi, Christoph Beglinger, Frank Serge Lehmann. 
Monoclonal antibody testing for fecal calprotectin is superior to polyclonal testing of fecal calprotectin and lactoferrin to identify organic intestinal disease in patients with abdominal discomfort. 

A prospective single-centre evaluation of the intra-individual variability of faecal calprotectin in quiescent Crohn’s disease. 

Value of fecal calprotectin in the evaluation of patients with abdominal discomfort: an observational study. 
BMC Gastroenterology 2012, 12:5.

5. Ronald Vermunt, Marcel van der Linden and Edwin Janssen. 
Calprotectin in biomarker-mediated drug development: Method validation for the quantification of fecal Calprotectin. 

Fecal calprotectin is equally sensitive in Crohn’s disease affecting the small bowel and colon. 

Fecal Calprotectin: Validation of a laboratory marker for Intestinal Inflammation. 
UEGW London, 2009 (Poster)

Stool Calprotectin as a Marker of Inflammation. 
UEGW London, 2009 (Poster).

Calprotectin levels in patients with idiopathic inflammatory bowel disease comparison of two commercial tests. 

Regional Hospital Grenaa – Department of Clinical Biochemistry, 2012.